The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...

US company IDEAYA Biosciences has exercised the option for an exclusive worldwide license for Biocytogen Pharmaceuticals’ ...

Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III ...